<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00999973</url>
  </required_header>
  <id_info>
    <org_study_id>8804</org_study_id>
    <nct_id>NCT00999973</nct_id>
  </id_info>
  <brief_title>Study on the Effect of Mitomycin C 0.02% on the Corneal Endothelial After Photorefractive Keratectomy in Moderate Myopia</brief_title>
  <official_title>Study on the Effect of Mitomycin C 0.02% on the Corneal Endothelial After Photorefractive Keratectomy in Moderate Myopia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study 126 eyes in 63 patients with moderate bilateral myopia and astigmatism between&#xD;
      -3 and -5 (SE difference between two eyes should not be more than 0.75 and the residual&#xD;
      corneal thickness&gt;350 Î¼ ) were entered in the study. One eye went randomly under PRK with&#xD;
      mitomycin C 0.02% in 15 min and then the other eye went under the operation without MMC.&#xD;
      UCVA,BCVA, refractory error after the operation and the number of endothelial cells before&#xD;
      and after the surgery would be compared in 6 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2009</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <number_of_arms>2</number_of_arms>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>Mitomycin c 0.02%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin C 0.02%</intervention_name>
    <arm_group_label>Mitomycin c 0.02%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  19 &lt; age &lt; 60&#xD;
&#xD;
          -  Refractory error stabled for at least one year&#xD;
&#xD;
          -  No corneal pathology&#xD;
&#xD;
          -  -3 &lt; bilateral myopia and astigmatism &lt; -5 with no difference more than 0.75 between 2&#xD;
             eyes&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Keratoconus&#xD;
&#xD;
          -  Ectatic corneal disease&#xD;
&#xD;
          -  Glaucoma&#xD;
&#xD;
          -  Corneal dystrophy&#xD;
&#xD;
          -  Lens changes affecting the visual acuity&#xD;
&#xD;
          -  Anterior or posterior uveitis&#xD;
&#xD;
          -  Corneal scar&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Mohammad Ali Javadi, MD</last_name>
    <phone>+982122585952</phone>
    <email>labbafi@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ophthalmic Research Center</name>
      <address>
        <city>Tehran</city>
        <zip>166666</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammad Ali Javadi, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <study_first_submitted>October 13, 2009</study_first_submitted>
  <study_first_submitted_qc>October 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2009</study_first_posted>
  <last_update_submitted>October 21, 2009</last_update_submitted>
  <last_update_submitted_qc>October 21, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2009</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

